GlucoVantage® (Dihydroberberine)

Evidence Level
Preliminary
2 Clinical Trials
4 Documented Benefits
1/5 Evidence Score

GlucoVantage® is NNB Nutrition's branded dihydroberberine (DHB), a reduced form of berberine that the body converts back to berberine. Two small absorption studies have tested it in people, and neither measured a health benefit. In a crossover study in five healthy young men, funded by NNB Nutrition, four doses of 100 mg DHB gave about 6.7 times the plasma berberine area under the curve and about 9 times the peak level of four doses of 500 mg berberine over two hours; baseline berberine differed between conditions, and glucose and insulin did not differ. In nine adults, a retail GlucoVantage product did not give significantly more blood berberine than a micellar berberine. Higher blood levels are not evidence of a greater effect. The blood sugar and cholesterol research often quoted for it used plain berberine, mostly in people with diagnosed type 2 diabetes or high cholesterol.

Studied Dose The absorption study gave 100 mg or 200 mg of dihydroberberine four times (with three meals the day before testing and with a test meal); a second study gave one dose of a retail product with 100 mg per capsule plus 5 mg black pepper extract. No trial has tested daily use or set an effective dose.
Active Compound Dihydroberberine (DHB), a reduced form of berberine made by NNB Nutrition by a patented process and sold as GlucoVantage®

Benefits

Higher plasma berberine than standard berberine after repeat doses

In a crossover study in five healthy young men, four doses of 100 mg dihydroberberine gave about 6.7 times the plasma berberine area under the curve and about 9 times the peak level of four doses of 500 mg berberine over two hours. Baseline berberine already differed between conditions, the maker funded the study, and higher blood levels do not show a greater effect.

Glucose and insulin after a test meal

The same study measured glucose and insulin for two hours after a test meal of glucose solution and white bread. Neither differed between 100 mg or 200 mg dihydroberberine, 500 mg berberine and placebo. The authors point to the short dosing and to participants with a normal insulin response; no longer human trial of dihydroberberine with results was found.

Blood berberine compared with a micellar berberine product

In nine healthy adults given one dose of either a retail GlucoVantage product, which also contained black pepper extract, or a micellar berberine, blood berberine over 24 hours was about 1.6 times higher with dihydroberberine, a difference that was not statistically significant. Several berberine breakdown products were higher. No health outcome was measured.

Blood sugar and lipid findings for plain berberine, a different product

Pooled trials of plain berberine in people with diagnosed type 2 diabetes found lower fasting glucose, after-meal glucose and HbA1c than control. Pooled trials in people with high blood lipids found lower total and LDL cholesterol and triglycerides, with most trials rated low in quality. These results are for standard berberine and cannot be carried over to dihydroberberine.

Mechanism of action

1

AMPK activation (laboratory and animal work)

A review of cell and animal studies of dihydroberberine names activation of AMPK, a cellular energy sensor, and of glucokinase, an enzyme that senses glucose, as key proposed targets. No human study has measured these effects of dihydroberberine.

2

Absorption and conversion back to berberine

Standard berberine is poorly absorbed, with under 1% reaching the blood, and causes more stomach upset at higher doses, according to the absorption study's authors. Dihydroberberine dissolves freely in water and is converted back to berberine in the gut by bacterial enzymes, according to a second study's authors. Both studies measured blood levels only, not tissue levels.

3

GLP-1: a marketing claim not measured in human studies

Marketing for this ingredient often mentions GLP-1, a gut hormone involved in appetite and blood sugar. Neither published human study of dihydroberberine measured GLP-1 or any other gut hormone, so no effect on GLP-1 has been shown, and this ingredient is not a substitute for any prescribed medication.

4

Gut bacteria and plain berberine

In a 3 month study in people with high blood lipids, plain berberine lowered blood lipids and its cholesterol drop tracked with changes in gut bacteria; mouse experiments suggested the bacteria were needed for the effect. Gut bacteria can also turn berberine into dihydroberberine. Neither finding shows that dihydroberberine supplements change gut bacteria in people.

Clinical trials

1
Dihydroberberine vs Berberine: Plasma Berberine Levels in Five Men
PubMed

Randomized, double-blind, placebo-controlled crossover pilot of four conditions (placebo, 500 mg berberine, and 100 mg or 200 mg dihydroberberine made by NNB Nutrition and sold as GlucoVantage), each taken as three doses with meals the day before testing plus one with a test meal. Funded by NNB Nutrition; the senior author is a paid advisor to NNB Nutrition (Moon et al. 2021, Nutrients)

Five healthy men, average age 26.

Over two hours, plasma berberine area under the curve was 284.4 with 100 mg dihydroberberine versus 42.3 ng/mL x 120 min with 500 mg berberine (about 6.7 times), and the peak level was 3.76 versus 0.4 ng/mL (about 9 times). Baseline berberine already differed between conditions (p = 0.006), and 200 mg did not differ significantly from 100 mg. Glucose and insulin did not differ across conditions. These are blood level measurements, not evidence of a greater effect.

2
Retail GlucoVantage Product vs Micellar Berberine: Blood Berberine Over 24 Hours
PubMed

Double-blind, randomized, two-arm parallel pilot: one dose of a retail product with 100 mg dihydroberberine (GlucoVantage) plus 5 mg black pepper extract per capsule, or a micellar berberine (LipoMicel), with blood sampled for 24 hours. Run by ISURA, a nonprofit; the micellar product's maker supplied its samples and its owner is a coauthor (Chang et al. 2024, Int J Mol Sci)

Nine healthy adults (five on dihydroberberine, four on micellar berberine).

Berberine area under the curve over 24 hours was about 1.6 times higher with dihydroberberine (41.1 versus 26.0 ng·h/mL), a difference that was not statistically significant; several berberine breakdown products were significantly higher. No adverse events were reported in either group. No health outcome was measured.

Side effects and drug interactions

Common Potential side effects

In the five-person absorption study, two participants reported 6 events while taking 100 mg dihydroberberine (nausea, headache and dizziness, two each; one rated moderate, the rest mild), compared with 3 on placebo and 1 each on 200 mg dihydroberberine and on berberine. No events were reported in the nine-person comparison study. Both studies were too small to judge tolerance.
Marketed as easier on the stomach than standard berberine because a smaller dose is used, but no cited study was designed or large enough to compare digestive side effects between the two forms.
Pregnancy, breastfeeding and infants: dihydroberberine is converted to berberine in the body. NIH advises that goldenseal, a berberine-rich herb, not be used in pregnancy or while breastfeeding or given to infants, because its berberine can be harmful to newborns. In laboratory work and in rats given berberine by injection, berberine pushed bilirubin off its carrier protein, and the author advised avoiding berberine-rich herbs in jaundiced newborns and pregnant women.
Animal safety data: in a 90 day rat study whose authors reported consulting ties to Nanjing Nutrabuilding Bio-Tech, no adverse effects were seen at the highest dose tested, 100 mg/kg body weight a day. No long-term human safety study of dihydroberberine is cited here.

Important Drug interactions

Many prescription drugs: in healthy men, 2 weeks of berberine at 300 mg three times a day reduced the activity of the liver enzymes CYP3A4, CYP2C9 and CYP2D6, which clear many medicines. Dihydroberberine itself was not tested, but it is converted to berberine and gave more blood berberine per milligram, so do not assume a smaller dose means a smaller interaction. Check with your pharmacist or doctor before combining.
Cyclosporine: berberine raised cyclosporine blood levels in kidney transplant recipients; do not combine without your transplant team.
Diabetes medicines: a berberine interaction review lists added glucose lowering, and a risk of low blood sugar, with sulfonylureas or insulin; with metformin, a goldenseal extract standardized to berberine lowered metformin blood levels in 16 healthy volunteers. Talk with your doctor before combining.
Warfarin and statins such as simvastatin or atorvastatin: the same review lists higher exposure through CYP2C9 or CYP3A4 slowing as possible, based on laboratory data with no human study of these pairs.
Drugs that affect heart rhythm (QT interval): the same review lists QT effects as possible from laboratory work and case reports, and a review of dihydroberberine flags hERG channel inhibition, a heart rhythm effect, as a risk needing careful evaluation.

Frequently asked questions about GlucoVantage® (Dihydroberberine)

What is GlucoVantage?

GlucoVantage® is NNB Nutrition's branded dihydroberberine (DHB), a reduced form of berberine that the body converts back to berberine. Two small absorption studies have tested it in people, and neither measured a health benefit.

What is GlucoVantage used for?

NutraSmarts does not list GlucoVantage under a health category. What the research covers: In a crossover study in five healthy young men, four doses of 100 mg dihydroberberine gave about 6.7 times the plasma berberine area under the curve and about 9 times the peak level of four doses of 500 mg berberine over two hours.

What is the recommended dosage of GlucoVantage?

The clinically studied dose is The absorption study gave 100 mg or 200 mg of dihydroberberine four times (with three meals the day before testing and with a test meal); a second study gave one dose of a retail product with 100 mg per capsule plus 5 mg black pepper extract. Always follow the product label and check with a healthcare provider for personal advice.

Is GlucoVantage safe, and does it have side effects?

Side effects and cautions reported for GlucoVantage include: In the five-person absorption study, two participants reported 6 events while taking 100 mg dihydroberberine (nausea, headache and dizziness, two each; one rated moderate, the rest mild), compared with 3 on placebo and 1 each on 200 mg dihydroberberine and on berberine. It may also interact with some medications. GlucoVantage is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does GlucoVantage interact with any medications?

Possible interactions include: Many prescription drugs: in healthy men, 2 weeks of berberine at 300 mg three times a day reduced the activity of the liver enzymes CYP3A4, CYP2C9 and CYP2D6, which clear many medicines. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for GlucoVantage?

NutraSmarts rates the evidence for GlucoVantage as Preliminary (1 out of 5). It is backed by 2 study summaries and 12 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(12 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients. 2021;14(1):124. doi: 10.3390/nu14010124.PubMedUsed to support: Randomized, double-blind, placebo-controlled crossover pilot in five healthy men, funded by NNB Nutrition; the senior author is a paid NNB Nutrition advisor. After four doses, 100 mg dihydroberberine (GlucoVantage) gave higher plasma berberine area under the curve (284.4 vs 42.3 ng/mL x 120 min) and peak (3.76 vs 0.4 ng/mL) than 500 mg berberine; baseline berberine differed between conditions (p = 0.006); glucose and insulin did not differ.
  2. Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, Ni J. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocr J. 2019;66(1):51-63. doi: 10.1507/endocrj.EJ18-0109.PubMedUsed to support: Systematic review and meta-analysis of 28 trials in 2,313 people with type 2 diabetes: plain berberine lowered fasting glucose, after-meal glucose and HbA1c more than control groups; the effect faded in trials longer than 90 days, at doses above 2 g a day and in people over 60. This evidence is for standard berberine in people with diabetes, not for dihydroberberine.
  3. Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25-34. doi: 10.1016/j.phymed.2018.09.212.PubMedUsed to support: Systematic review and meta-analysis of 16 trials with 2,147 participants with high blood lipids: plain berberine lowered total cholesterol, LDL cholesterol and triglycerides; the authors rated most trials low in quality and heterogeneous. This evidence is for standard berberine, not dihydroberberine, and the review did not measure body weight.
  4. Wu C, Zhao Y, Zhang Y, Yang Y, Su W, Yang Y, Sun L, Zhang F, Yu J, Wang Y, Guo P, Zhu B, Wu S. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients. J Adv Res. 2022;37:197-208. doi: 10.1016/j.jare.2021.07.011.PubMedUsed to support: Three month study in people with high blood lipids plus mouse experiments: plain berberine lowered serum lipids with wide individual variation, its cholesterol lowering tracked with gut bacteria changes, and in mice the gut microbiome was needed for the lipid effect. This is work on plain berberine, not dihydroberberine.
  5. Chang C, Roh YS, Du M, Kuo YC, Zhang Y, Hardy M, Gahler R, Solnier J. Differences in Metabolite Profiles of Dihydroberberine and Micellar Berberine in Caco-2 Cells and Humans-A Pilot Study. Int J Mol Sci. 2024;25(11):5625. doi: 10.3390/ijms25115625.PubMedUsed to support: Double-blind, randomized parallel pilot in nine healthy adults: one dose of a retail GlucoVantage product (100 mg dihydroberberine plus 5 mg black pepper extract per capsule) or a micellar berberine. Blood berberine over 24 hours was about 1.6 times higher with dihydroberberine, not statistically significant; several metabolites were higher; no adverse events were reported. ISURA is a nonprofit; the micellar product's maker supplied samples and its owner is a coauthor.
  6. Lewis KD, Falk M. Toxicological assessment of dihydroberberine. Food Chem Toxicol. 2022;168:113301. doi: 10.1016/j.fct.2022.113301.PubMedUsed to support: Laboratory and rat toxicology of dihydroberberine: no mutagenic or chromosome-damaging effects in standard tests, oral LD50 above 2000 mg/kg in rats, and a no-observed-adverse-effect level of 100 mg/kg a day, the highest dose tested, in a 90 day rat study. Both authors reported consulting ties to Nanjing Nutrabuilding Bio-Tech, which provided financial support.
  7. Wang D, Tang Y. Dihydroberberine in metabolic disorders: Bioavailability, molecular mechanisms, toxicology, and future perspectives. Food Chem Toxicol. 2026;216:116267. doi: 10.1016/j.fct.2026.116267.PubMedUsed to support: Narrative review of mostly preclinical dihydroberberine research: cell and animal work points to AMPK and glucokinase activation; gut bacteria both produce and respond to dihydroberberine; toxicology looked favorable, but possible hERG channel inhibition needs careful evaluation; human trials of health outcomes remain highly limited.
  8. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-7. doi: 10.1007/s00228-011-1108-2.PubMedUsed to support: Randomized crossover study in healthy men: 2 weeks of berberine 300 mg three times a day reduced CYP2D6, CYP2C9 and CYP3A4 activity measured with probe drugs; midazolam exposure rose about 40%. The authors advise considering drug interactions.
  9. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-72. doi: 10.1007/s00228-005-0952-3.PubMedUsed to support: Randomized controlled study in kidney transplant recipients: berberine 0.2 g three times a day raised blood levels of the immunosuppressant cyclosporine; in a 6-patient pharmacokinetic study cyclosporine exposure rose 34.5%.
  10. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63(4):201-8. doi: 10.1159/000243932.PubMedUsed to support: Laboratory and rat study: berberine pushed bilirubin off its carrier protein albumin far more strongly than a known displacing drug and raised unbound bilirubin in rats. The author advises avoiding berberine-rich herbs in jaundiced newborns and pregnant women.
  11. National Center for Complementary and Integrative Health (NCCIH). Goldenseal: Usefulness and Safety NCCIH, National Institutes of Health. 2025;Last updated February 2025. https://www.nccih.nih.gov/health/goldenseal.SourceUsed to support: Not PubMed-indexed (NIH fact sheet, read 2026). States that women who are pregnant or breastfeeding should not use goldenseal, that it should not be given to infants, that its berberine constituent can be harmful to newborns, and that goldenseal may change the way the body processes many medications.
  12. Dumitru CN, Marcu T, Dumitru AO, Tudor SS, Ferțu ID, Elisei AM, Goroftei L. Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review. Pharmaceuticals (Basel). 2026;19(8):1313. doi: 10.3390/ph19081313.PubMedUsed to support: Narrative review of berberine drug interactions: human evidence for cyclosporine and probe drugs; CYP3A4, CYP2D6 and CYP2C9 inhibition; a goldenseal extract standardized to berberine lowered metformin exposure in 16 healthy volunteers; added low blood sugar risk with diabetes drugs and QT effects listed as possible. Warfarin and statin interactions are rated in vitro or mechanistic only, with no human study of those pairs.